Torrent Pharma Peer Comparison
NSE: TORNTPHARM | BSE: 500420
₹4,772.00
₹0.00 (0.00%)As on 06-Oct-2026IST
Market cap
₹1,81,740 Cr
Revenue (TTM)
₹15,723 Cr
P/E Ratio
83.3
P/B Ratio
20.2
Div. Yield
0.8 %
| Torrent Pharma | Sun Pharmaceutical | Cipla | Zydus Lifesciences | Mankind Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
1,81,740 | 4,32,120 | 1,08,497 | 1,15,710 | 1,02,650 |
Revenue (₹ Cr) |
15,723 | 59,911 | 28,324 | 28,592 | 14,738 |
Net Profit (₹ Cr) |
2,156.00 | 12,172.70 | 3,364.84 | 4,492.20 | 2,055.11 |
Net Margin (%) |
13.77 | 19.41 | 11.54 | 14.92 | 13.64 |
RoE (%) |
26.88 | 15.65 | 10.63 | 18.78 | 13.60 |
Price to Earnings |
83.33 | 35.73 | 32.19 | 25.64 | 50.25 |
Price-To-Book |
20.25 | 5.00 | 3.09 | 4.29 | 6.10 |
Income Statement (₹ Cr)
| Torrent Pharma | Sun Pharmaceutical | Cipla | Zydus Lifesciences | Mankind Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
15,723.00 | 59,910.52 | 28,324.40 | 28,591.70 | 14,737.88 |
|
Total Income
|
15,654.00 | 62,725.79 | 29,158.75 | 30,111.40 | 15,061.79 |
|
Total Expenditure
|
10,532.00 | 42,647.50 | 22,985.32 | 21,334.70 | 10,911.05 |
|
EBITDA
|
5,191.00 | 17,263.02 | 5,339.08 | 7,257.00 | 3,826.83 |
|
Depreciation
|
1,511.00 | 2,976.02 | 1,304.52 | 1,724.60 | 893.20 |
|
EBIT
|
3,680.00 | 14,287.00 | 4,034.56 | 5,532.40 | 2,933.63 |
|
Interest
|
634.00 | 363.78 | 57.37 | 510.20 | 578.61 |
|
Other Income
|
-69.00 | 2,815.27 | 834.35 | 1,519.70 | 323.91 |
|
Exceptional Items
|
-110.00 | -693.57 | -275.91 | -534.80 | -129.75 |
|
Profit before Tax
|
2,867.00 | 16,044.92 | 4,535.63 | 6,007.10 | 2,549.18 |
|
Provision for Tax
|
711.00 | 3,872.22 | 1,170.79 | 1,514.90 | 494.07 |
|
Profit after Tax
|
2,156.00 | 12,172.70 | 3,364.84 | 4,492.20 | 2,055.11 |
Liabilities (₹ Cr)
| Torrent Pharma | Sun Pharmaceutical | Cipla | Zydus Lifesciences | Mankind Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
8,389.00 | 83,570.09 | 34,431.95 | 27,111.40 | 16,300.34 |
|
Minority Interest
|
25.00 | -21.43 | 14.98 | -79.70 | -24.90 |
|
Non-Current Liabilities
|
18,384.00 | 2,283.44 | 962.15 | 7,112.50 | 5,011.23 |
|
Current Liabilities
|
8,343.00 | 22,622.04 | 7,013.59 | 15,711.90 | 6,507.25 |
|
Total Liabilities
|
43,613.69 | 1,08,407.20 | 42,342.71 | 50,672.60 | 27,754.83 |
Assets (₹ Cr)
| Torrent Pharma | Sun Pharmaceutical | Cipla | Zydus Lifesciences | Mankind Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
33,955.00 | 43,711.29 | 15,471.21 | 31,677.20 | 20,274.65 |
|
Current Assets
|
9,392.00 | 63,860.29 | 24,145.86 | 19,906.10 | 6,954.20 |
|
Total Assets
|
43,613.69 | 1,08,407.20 | 42,342.71 | 50,672.60 | 27,754.83 |
|
Total Debt*
|
14,798.24 | 4,081.61 | 257.97 | 11,769.50 | 6,021.78 |
|
Net Current Assets
|
1,049.00 | 41,238.25 | 17,132.27 | 4,194.20 | 446.95 |
|
Contingent Liabilities
|
379.25 | 1,587.05 | 987.37 | 989.90 | 924.77 |
Cashflow (₹ Cr)
| Torrent Pharma | Sun Pharmaceutical | Cipla | Zydus Lifesciences | Mankind Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
3,022.71 | 12,419.18 | 3,940.02 | 2,116.60 | 3,121.29 |
|
Cash Flow from Investing Activities
|
-12,712.41 | -11,344.05 | -2,326.13 | -8,296.10 | -196.42 |
|
Cash from Financing Activities
|
10,150.60 | -2,512.55 | -1,233.65 | 5,806.90 | -2,952.69 |
|
Net Cash Inflow / Outflow
|
460.90 | -1,437.42 | 380.24 | -372.60 | -27.82 |
Ratios
Profitability Ratios
| Torrent Pharma | Sun Pharmaceutical | Cipla | Zydus Lifesciences | Mankind Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
19.27 | 19.11 | 16.00 | 21.39 | 13.24 |
|
ROE (%)
|
26.88 | 15.65 | 10.63 | 18.78 | 13.60 |
|
ROA (%)
|
7.27 | 12.12 | 8.42 | 10.03 | 7.36 |
|
EBIT Margin (%)
|
23.41 | 23.85 | 14.24 | 19.35 | 19.91 |
|
Net Margin (%)
|
13.77 | 19.41 | 11.54 | 14.92 | 13.64 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Torrent Pharma | Sun Pharmaceutical | Cipla | Zydus Lifesciences | Mankind Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
32.85 | 11.41 | 1.85 | 21.11 | 14.16 |
|
EBIT Growth (%)
|
20.66 | 8.10 | -33.61 | -8.99 | 19.45 |
|
Net Profit Growth (%)
|
7.69 | 16.92 | -37.77 | -3.14 | 8.09 |
|
EPS Growth (%)
|
12.04 | 10.18 | -33.63 | 4.31 | 12.27 |
|
Book Value Growth (%)
|
10.51 | 15.72 | 10.59 | 13.19 | 13.74 |
Valuation Ratios
| Torrent Pharma | Sun Pharmaceutical | Cipla | Zydus Lifesciences | Mankind Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
71.45 | 34.21 | 30.31 | 23.68 | 47.76 |
|
Price / Book Value
|
20.25 | 5.00 | 3.09 | 4.29 | 6.10 |
|
Dividend Yield (%)
|
0.80 | 0.89 | 0.97 | 0.09 | 0.04 |
|
EV/EBITDA
|
37.47 | 23.38 | 18.69 | 16.58 | 27.87 |
|
Market Cap (₹ Cr)
|
1,42,851.87 | 4,21,639.92 | 98,797.18 | 87,643.18 | 82,801.75 |
Solvency Ratios
| Torrent Pharma | Sun Pharmaceutical | Cipla | Zydus Lifesciences | Mankind Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
1.39 | 0.00 | 0.00 | 0.12 | 0.17 |
|
Short term debt to equity ratio
|
0.35 | 0.05 | 0.00 | 0.16 | 0.04 |
|
Current Ratio
|
1.13 | 2.82 | 3.44 | 1.27 | 1.07 |
|
Quick Ratio
|
0.75 | 2.31 | 2.50 | 0.91 | 0.74 |
|
Interest Coverage
|
5.52 | 45.11 | 80.06 | 12.77 | 5.41 |
Operating Efficiency Ratios
| Torrent Pharma | Sun Pharmaceutical | Cipla | Zydus Lifesciences | Mankind Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
19.28 | 25.89 | 19.84 | 18.94 | 11.74 |
|
Asset Turnover
|
0.53 | 0.60 | 0.71 | 0.64 | 0.53 |
|
Receivable days
|
45.41 | 89.14 | 52.05 | 33.55 | 39.93 |
|
Inventory Days
|
52.67 | 67.85 | 57.25 | 33.80 | 51.78 |
|
Payable days
|
244.06 | 213.72 | 115.96 | 149.82 | 111.46 |
|
Cash Conversion Cycle
|
-145.98 | -56.72 | -6.65 | -82.46 | -19.75 |